Navigation Links
deCODE genetics Announces Third Quarter 2007 Financial Results
Date:11/5/2007

1.3 million, compared to $42.9 million for the first nine months of 2006. Our research and development expense this year reflects the advancement of our drug development programs, the launch of our first three DNA-based tests for gauging individual risk of common diseases, and the acceleration of our gene and target discovery work in several major disease areas.

Selling, general and administrative expense for the third quarter of 2007 was $7.1 million, compared to $6.9 million for the 2006 period. For the first nine months of the year, SG&A expense was $19.4 million in 2007 and $16.6 million in 2006. The increases in SG&A expense year-on-year reflect the build- up of our diagnostics business as well as increased salary and stock-based compensation expense in the 2007 periods.

At September 30, 2007, the company had $118.6 million in cash, cash equivalents and investments, including restricted cash equivalents, compared to $152.0 million at December 31, 2006.

"The success of our gene discovery work is giving us a steady stream of novel targets for both diagnostics and therapeutics in major therapeutic areas. With the launch of deCODE AF(TM) and deCODE MI(TM), we have continued in the past quarter to expand our portfolio of DNA-based risk predisposition tests, offering new tools for focusing and improving disease prevention. More such products, including tests in glaucoma and other conditions, as well as a service through which individuals can begin to learn about their own genome, are on the way in the coming months," said Kari Stefansson, CEO of deCODE.

"In our drug development program targeting the leukotriene pathway for the prevention of heart attack, DG051 is now in a phase IIa trial that will aid us in dose selection for a larger Phase II study scheduled for early next year, and we expect to complete our bioequivalence analysis for our lead reformulation for DG031 before the end of 2007. With DG041, our Phase II anti- platelet compound, w
'/>"/>

SOURCE deCODE genetics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
2. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
3. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
4. Response Genetics Reports Second Quarter 2007 Financial Results
5. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
6. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
7. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
8. Interleukin Genetics Announces Management and Board Appointments
9. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
10. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
11. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014  ( ... that CoPatient, an online medical bill review and advocacy ... offering in the FREE WellCard Savings discount health services ... medical bill that was more than they expected to ... members reduce health care costs, WellCard Savings is pleased ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
(Date:12/19/2014)... OR and Hershey, PA (PRWEB) December 19, 2014 ... Pink: BJCT), a leading developer and manufacturer of ... entered into an agreement with Immunomic Therapeutics, Inc. ... Biojector®-2000 needle-free injection device with its LAMP™ vaccine ... an option for an exclusive Worldwide license to ...
(Date:12/19/2014)... 19, 2014 BioPlus Specialty Pharmacy ... announces the promotion of Nick Maroulis, Pharm.D. to the ... Services. , In this position, Dr. Maroulis will ... managing the directors of our multi-site pharmacies as the ... 1997 and during that time he has served in ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... and AALST , Belgium, AHMEDABAD, India and ... genae associates,Cardiovascular Center Aalst and J.B. Dahm, ... Core Laboratories joint venture, called imaeon., ... of medical images,analysis for clinical research projects, ...
... EDMONTON, Oct. 6 /PRNewswire-FirstCall/ - BioMS Medical ... of multiple sclerosis (MS), today,announced that the independent ... II MINDSET-01 trial of dirucotide (MBP8298) in patients,with ... recommended,that the trial continue as per the protocol., ...
... focus on a new dietary supplement resulting from years of, ... ... Del-Immune V, BOULDER, Colo., Oct. 6 On ... regulatory,cytokines Del-Immune V(R) induction and its impact on cytotoxicity of,natural killer cells" ...
Cached Biology Technology:Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm 2BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board 2EUPROBIO 2008 Presentation to Highlight Latest Immune Research 2
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... and security consultant, Apollo Robbins for the ... wallet.  Apollo Robbins will ... th , 2015, demonstrating some of his famous theft ...
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ... Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter security ... 3.6% from 2014 to 2019. Although the U.S. market ... Canada is expected to grow at a ...
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... An accidental discovery in a laboratory at Oregon State University ... has absorbed the energies of ancient Egyptians, the Han dynasty ... a near-perfect blue pigment. Through much of recorded human ... could be used to paint things blue, often with limited ...
... are a serious threat to human society. They are also ... at the University of Gothenburg are attempting to find substances ... ensure that the drugs of today remain effective into the ... particularly serious in drugs against fungi. Fungal cells are similar ...
... This release is available in German . ... in the cells of their victim in order to ,reprogram, them. ... live, making lots of new viruses instead. Luckily, in ... ensured by the cells, own sensors that recognise alien genetic material. ...
Cached Biology News:Accidental discovery produces durable new blue pigment for multiple applications 2Slowing evolution to stop drug resistance 2Study shows link between influenza virus and fever 2
Lentigen's manufacturing platform is sufficiently versatile for use in the manufacture of any HIV-based Lentiviral vector. Lentigen will manufacture your LV of choice to the highest possible titer a...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: